Aoife Brennan
Directeur/Membre du Conseil chez FIBROGEN, INC.
Fortune : 51 833 $ au 30/04/2024
Profil
Aoife M.
Brennan is currently the President, Chief Executive Officer & Director at Synlogic Operating Co., Inc. She is also a Director at FibroGen, Inc., Cerevance, Inc., and an Advisor at Atlas Venture Advisors, Inc. Previously, she held the positions of President, Chief Executive Officer & Director at Synlogic, Inc. from 2016 to 2024, Director-Clinical Development at Tolerx, Inc. from 2008 to 2011, Independent Director at Ra Pharmaceuticals, Inc. from 2018 to 2020, and Vice President & Head-Rare Disease Innovation Unit at Biogen, Inc. from 2011 to 2016.
Dr. Brennan holds a doctorate degree from Trinity College Dublin and a graduate degree from Harvard Medical School (conferred in 2008).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SYNLOGIC INC
0,15% | 10/11/2023 | 17 087 ( 0,15% ) | 31 782 $ | 30/04/2024 |
FIBROGEN, INC.
0,02% | 31/03/2024 | 19 658 ( 0,02% ) | 20 051 $ | 30/04/2024 |
Postes actifs de Aoife Brennan
| Sociétés | Poste | Début |
|---|---|---|
| FIBROGEN, INC. | Directeur/Membre du Conseil | 05/08/2020 |
Synlogic Operating Co., Inc.
 Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Directeur Général | 01/05/2018 |
Cerevance, Inc.
 Cerevance, Inc. Medical SpecialtiesHealth Technology Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA. | Directeur/Membre du Conseil | 01/01/2020 |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | - |
Anciens postes connus de Aoife Brennan
| Sociétés | Poste | Fin |
|---|---|---|
| SYNLOGIC, INC. | Directeur Général | 09/03/2024 |
| RA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 02/04/2020 |
| BIOGEN INC. | Corporate Officer/Principal | 01/08/2016 |
Tolerx, Inc.
 Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Corporate Officer/Principal | 01/04/2011 |
Formation de Aoife Brennan
| Trinity College Dublin | Doctorate Degree |
| Harvard Medical School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| SYNLOGIC, INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| FIBROGEN, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Health Technology |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Cerevance, Inc.
Cerevance, Inc. Medical SpecialtiesHealth Technology Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA. | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
